HTR1A and insomnia measurement: Compared to the insomnia model group, MSEOs treatment resulted in increased levels of 5HT-1A in the cerebral cortex, hypothalamus, and hippocampus of mice across three dosage groups, with the MSEOs-H group showing the most favorable results in the hippocampus and hypothalamus (p < 0.05) (Fig. 5B).